Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma

This publication has 17 references indexed in Scilit:

• Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases
  British Journal of Cancer, 1987
• Serum ca 50 as a tumor marker in pancreatic cancer: A comparison with CA 19‐9
  International Journal of Cancer, 1987
• Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9
  International Journal of Cancer, 1986
• The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant liver diseases
  British Journal of Surgery, 1986
• Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis
  British Journal of Cancer, 1986
• Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1985
• Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study
  Cancer, 1985
• Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bank
  International Journal of Cancer, 1984
• Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.
  Journal of Clinical Pathology, 1984
• DISTRIBUTION OF 5 ANTIGENS IN HEPATOCELLULAR CARCINOMA
  1979